logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
01-Aug-2016 To 30-Sep-2016
MediciNova Inc
Interim efficacy analysis of Phase 2b Trial of MN-166
Progressive multiple sclerosis
Aug 2016
Auris Medical Holding AG
First topline phase 3 trial data for AM-101 (TACTT2)
Acute inner ear tinnitus
2H 2016
RedHill Biopharma Ltd.
Interim analysis of phase 3 study of RHB-104
Crohn’s disease
2H 2016
RedHill Biopharma Ltd.
Topline results from phase 3 study of BEKINDA
Gastroenteritis
Q3 2016
Array BioPharma Inc.
Topline results from phase 3 trial of Binimetinib (COLUMBUS)
BRAF-mutant melanoma
2H 2016
Array BioPharma Inc.
Topline results from phase 3 trial of Selumetinib (SELECT-1)
KRAS-mutant non-small cell lung cancer
2H 2016
Tesaro Inc.
NDA submission for Niraparib
Ovarian cancer
2H 2016
SAGE Therapeutics, Inc.
Top-line Results of phase 3 study of SAGE-547 (STATUS)
Super-refractory status epilepticus (SRSE)
2H 2016
Regulus Therapeutics Inc.
Data from phase 1 study of RG-101
Hepatitis C infected subjects with severe renal insufficiency
Q3 2016
Ariad Pharmaceuticals Inc
File NDA for Brigatinib
Refractory non-small cell lung cancer
2H 2016
Genocea Biosciences, Inc.
Clinical efficacy data from phase 2b study of GEN-003
Genital herpes
Q3 2016
Aerie Pharmaceuticals, Inc.
Topline 90-day efficacy data from 1st phase 3 trial of Roclatan (Mercury 1)
To lower intraocular pressure (IOP) in patients with glaucoma
Early Q3 2016
Infinity Pharmaceuticals Inc.
Topline data from Phase 2 study of duvelisib (DYNAMO)
Refractory indolent non-Hodgkin lymphoma
2H 2016
Infinity Pharmaceuticals Inc.
Report topline data from phase 3 study of duvelisib (DUO)
Relapsed/refractory chronic lymphocytic leukemia (CLL)
2H 2016
Amicus Therapeutics Inc.
Topline data from phase 3 study of SD-101
Epidermolysis Bullosa
2H 2016
Kite Pharma, Inc.
Interim phase 2 pivotal data KTE-C19 (ZUMA-1)
Refractory Aggressive Non-Hodgkin Lymphoma
Q3 2016
Novavax Inc.
Topline data from phase 3 pivotal RSV F Vaccine in older adults (Resolve)
Moderate-severe RSV-associated lower respiratory tract disease
2H 2016
Novavax Inc.
Topline data from Phase 2 RSV F Vaccine rollover trial in older adults
Respiratory syncytial virus infection
2H 2016
OPKO Health Inc.
Topline results fom phase 3 trial of hGH-CTP in adults
Growth hormone deficiency
2H 2016
Dimension Therapeutics, Inc.
Cohort data from phase 1/2 trial of DTX101
Moderate/severe to severe hemophilia B;
Q3 2016
Windtree Therapeutics Inc.
Topline results from phase 2a trial of AEROSURF
Respiratory distress syndrome
Late Q3 2016
Recro Pharma Inc.
Topline data from phase 3 trial of IV Meloxicam
Bunionectomy Surgery
2H 2016
SOLIGENIX, INC.
Results from phase 3 study of SGX301
Cutaneous T-cell lymphoma
Q3 2016
Achillion Pharmaceuticals Inc.
Interim results from phase 1a healthy-volunteer multiple-ascending dose trial of ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
2H 2016
Alkermes plc
Submit sNDA for ARISTADA to support dosing once every two months.
Schizophrenia